Patent Law Could Also Limit Mifepristone Access
Existing patents deter the marketing of more affordable generic drugs that could be used off-label for abortions.
The Growth in Business Support for Regulation
Businesses in the United States are increasingly supporting regulation and regulators against judicial decisions curtailing agency authority.
FDA’s Role in Access to Reproductive Health Care
Recent abortion pill litigation underscores the significance of calls to make birth control pills available over the counter.
The Supreme Court and the Future of the Internet
Upcoming Supreme Court decisions may reshape the legal risks facing tech companies.
School Transportation and Educational Equity
School transportation resources must increase to achieve mobility justice.
Sustainable Transportation for Rural Communities
Regulators must redress transportation inequities in rural and disadvantaged communities.
Opening the Skies to Passengers Who Use Wheelchairs
Airline transportation needs to address accessibility issues for passengers with disabilities.
Disability and the Right to Move in the World
Current regulations limit accessibility of air travel to people with disabilities.
Merger Law Is Dante’s Inferno Revisited
The shift by agencies away from the current guidelines on mergers and acquisitions has left firms in limbo.
Jimmy Carter, The Great Deregulator
By pushing for deregulation and adopting other reforms, President Carter left an enduring legacy on the U.S. regulatory system.
FDA, Not a Federal Judge, Should Decide on Abortion Drugs
Anti-abortion advocates take aim at FDA approval and regulation of the abortion drug mifepristone, threatening access nationwide.
FDA Advances Program for Real-World Evidence
FDA’s approach to evidence-based decision-making may not be addressed to the right people.